한국어
English
日本語
中文(简体)
BOSULIF 100 mg (Bosutinib Hydrate)
103.4mg
Tablet · Prescription medication
Pfizer Korea Co., Ltd.
Bosutinib hydrate is an active ingredient used for the treatment of chronic myeloid leukemia.
MFDS ingredient code M266097
Bosutinib hydrate belongs to the class of anticancer drugs known as tyrosine kinase inhibitors and is used to treat certain hematological cancers, such as chronic myeloid leukemia. This ingredient is included in medications with the purpose of inhibiting the growth and division of cancer cells.
Bosutinib hydrate blocks a specific enzyme known as tyrosine kinase within cancer cells, disrupting the signaling that leads to cancer cell proliferation. As a result, the growth and spread of cancer cells can be inhibited, potentially slowing disease progression.
Approved uses differ by product. Check each product's information for its actual use.
Bosutinib hydrate is effective against specific mutations compared to other tyrosine kinase inhibitors and is differentiated in terms of its side effect profile and drug interactions. This makes it suitable for personalized treatment tailored to the patient's condition.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
3 total
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.
